5 of 10
Baxter International
Ticker: BAX
Market cap: $33 billion
2008 revenue: $12.3 billion
P/E ratio: 13 *
Dividend yield: 2.1%

Like Amedisys, Baxter, which sells products ranging from drugs for rare blood disorders to IV tubes, wasn't immune to the pox on medical-related shares this year.

Its stock has limped to a 1% gain year to date, vs. 21% for the S&P, and its P/E of 13 is well below its 10-year average of 19.

Wyatt Crumpler, manager of American Beacon Large Cap Value Fund, which owns Baxter shares, says it has been unfairly lumped in with companies that could suffer if health-care reform passes.

"The whole sector has been tainted," he says. "Baxter is a key provider of services and is in a good competitive position. Government changes won't affect that."

Baxter makes a wide range of indispensable products, which are likely to prosper regardless of potential changes like cost cutting or increased generic drug use.

Moreover, Baxter currently garners 60% of its sales from outside the U.S., and Piper Jaffray analyst Matt Miksic expects significant growth in those regions.

The company aims at highly specific markets, generating dependable revenues from products such as syringes and dialysis systems, and from treatments for hemophilia.

That mix has led Baxter to deliver double-digit annual earnings growth over the past five years. CEO Bob Parkinson is confident enough that he recently predicted profits will increase by 11% to 13% annually over the next five years.

They may rise even higher: Baxter has a deep pipeline of innovative products, including an antibody replacement therapy, IVIG , that is being tested as a treatment for Alzheimer's.

If that succeeds, it will be a "game changer," says Leerink Swann analyst Rick Wise. Vaccines also offer potential, he says. "They're one of the few companies that could be a major player there."

Next quarter, Baxter expects to reap more than $30 million in profits from its swine flu vaccine, Celvapan -- a shot in the arm for the bottom line.

NEXT: Quanta
Last updated December 09 2009: 10:19 AM ET
Email | Print | Share  |  RSS
google my aol my msn my yahoo! netvibes
Paste this link into your favorite RSS desktop reader
See all CNNMoney.com RSS FEEDS (close)
* Price/earnings ratios based on estimated 2010 earnings.
Stock picks from 5 pros With economic uncertainty near an all-time high, we sought the advice of some of the smartest market watchers we know. More
4 tech trends to watchTech investing is all about the next big thing. Here are the trends that could really pay off. More
3 ways to outwit the market At times the market acts the fool. Protecting yourself from its folly is simpler than you might think. More

Most stock quote data provided by BATS. Market indices are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer. Morningstar: © 2018 Morningstar, Inc. All Rights Reserved. Factset: FactSet Research Systems Inc. 2018. All rights reserved. Chicago Mercantile Association: Certain market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved. Dow Jones: The Dow Jones branded indices are proprietary to and are calculated, distributed and marketed by DJI Opco, a subsidiary of S&P Dow Jones Indices LLC and have been licensed for use to S&P Opco, LLC and CNN. Standard & Poor's and S&P are registered trademarks of Standard & Poor's Financial Services LLC and Dow Jones is a registered trademark of Dow Jones Trademark Holdings LLC. All content of the Dow Jones branded indices © S&P Dow Jones Indices LLC 2018 and/or its affiliates.